Johnson & Johnson (JNJ) Tops Q2 EPS by 10c, Beats on Revenue; Offers FY24 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
Go back to Johnson & Johnson (JNJ) Tops Q2 EPS by 10c, Beats on Revenue; Offers FY24 EPS Guidance
July 17, 2024 6:20 AM EDT
2024 Second-Quarter reported sales growth of 4.3% to $22.4 Billion with operational growth of 6.6%* and adjusted operational growth of 6.5%*. Adjusted operational growth excluding COVID-19 Vaccine of 7.1%*
2024 Second-Quarter Earnings per share (EPS) of $1.93 decreasing by 5.9% due to one-time special charges and adjusted EPS of $2.82 increasing by 10.2%*
Significant new product pipeline progress including TREMFYA IBD and subcutaneous filings, RYBREVANT subcutaneous filing, and VARIPULSE admIRE data release
Company increases Full-Year 2024 operational sales5 guidance to reflect the acquisition of Shockwave Medical
Company updates Full-Year 2024 adjusted operational EPS guidance to reflect improved performance; costs associated... More
